Supplemental Material for: Curative Locoregional Therapy Following Objective Response to Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
figshare admin karger, Yu‐Yun Shao, San‐Chi Chen, Kun-Ming Rau et autres
Introduction: Atezolizumab plus bevacizumab (Atezo-Bev) is a standard first-line systemic therapy for unresectable hepatocellular carcinoma (HCC). We aimed to explore the benefits of adding curative locoregional therapy (LRT) to patients who achieve a partial response to Atezo-Bev treatment. Methods: This multinational retrospective …
ch (code pays fourni par la source)
0 citations
Figshare